BackArriVent BioPharma Overview

ArriVent BioPharma Selling, General & Admin

Selling, General & Admin expenses for AVBP.

Quarterly SG&A Expenses

$8.49M
↑ 54.92% YoY

As of Mar 31, 2026

Annual SG&A Expenses (TTM)

$27.19M
↑ 59.14% YoY

Trailing 12 months ending Mar 31, 2026

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin